Examining the link between plasma MRD and HPV DNA in advanced cervical cancer treatment outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between plasma minimal residual disease (MRD) and circulating free DNA (cfDNA) from HPV in patients with locally advanced cervical cancer undergoing concurrent chemoradiotherapy. By utilizing liquid biopsy techniques, the study aims to analyze the expression levels of MRD and plasma HPV before and after treatment to predict the efficacy of the therapy and assess the risk of disease recurrence. The findings could provide insights into the prognostic value of these biomarkers in managing cervical cancer.

Why it matters

Who can join: the full rules

Inclusion criteria

* Age: ≥ 18 years old, ≤ 75 years old.
* Pathological histologic confirmation of cervical cancer.
* Imaging or PET/CT examination can be performed to understand the tumor and complete all follow-up.
* Measurable lesions before treatment.
* Good physical condition: ECOG score 0-1 (or KPS score 70-100).
* Estimated survival≥ 6 months.
* The baseline blood routine and biochemical indexes before radiotherapy and chemotherapy met the following standards: hemoglobin ≥ 80g/L, absolute neutrophil count (ANC) ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT, AST ≤ 2.5 times the normal upper limit; Serum albumin ≥ 30 g/L.
* There are three preoperative items: if the patient has syphilis, plum repellent therapy is required before treatment.
* The patient has no history of allergy to rubber products.
* Cardiopulmonary function is basically normal

Exclusion Criteria:

* Those who are allergic to rubber products.
* Those with severe acute infection and uncontrolled or purulent and chronic infection wounds that do not heal, chronic hepatitis B active stage, active tuberculosis, syphilis outbreak and AIDS.
* Patients with pre-existing severe heart disease, including: congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and intractable hypertension.
* Those with neurological or psychiatric diseases or mental disorders that are not easy to control, poor compliance, unable to cooperate with and describe treatment responses, uncontrolled primary brain tumors or central nervous system metastases, and those with obvious cranial hypertension signs or neuropsychiatric symptoms.
* with malignant serous effusion.
* History of severe enteritis and cystitis, bleeding, intestinal perforation, rectovaginal fistula, rectoval bladder fistula, etc.
* Those who have participated in other clinical trials.
* Other situations in which the investigator believes that the subject is not suitable to participate in this experiment

Where it's running

• Yong Li
  Guiyang, Guizhou, China Recruiting

Study contacts

• Study coordinator: Yong Li, Chief physician
• Email: liyong7229771@163.com
• Phone: 13628566285

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Iparomlimab/Tuvonralimab with nab-paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer

  This trial tests whether adding Iparomlimab/Tuvonralimab to nab-paclitaxel and cisplatin before surgery can shrink locally advanced cervical cancer and safely be given to adult women.

  Recruiting Phase 2 Xijing Hospital · Xi'an, Shaanxi · NCT07876154

• Vitamin D Status and Outcomes in Locally Advanced Cervical Cancer treated with chemoradiotherapy

  This study tests whether pretreatment vitamin D levels can predict how well women with locally advanced cervical cancer respond to standard chemoradiotherapy.

  Recruiting University of Kragujevac · Kragujevac, Šumadija · NCT07743918

• Patient-tailored 3D-printed ARCHITECT applicator for cervical cancer brachytherapy

  We’re testing a 3D-printed, one-time use ARCHITECT applicator to see if it safely helps deliver brachytherapy for locally advanced cervical cancer.

  Recruiting Erasmus Medical Center · Rotterdam · NCT07435987

• Nanocrystalline megestrol acetate with chemoradiation for locally advanced cervical cancer

  This Phase 1 trial tests whether taking nanocrystalline megestrol acetate by mouth can prevent or reduce weight and muscle loss in adults with locally advanced cervical cancer who are receiving concurrent chemoradiotherapy.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT07338487

• Cadonilimab plus cisplatin given before surgery for locally advanced cervical cancer

  This study will test whether giving cadonilimab together with cisplatin before surgery helps people with resectable, locally advanced cervical cancer.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT07104149

• Pre-surgery iparomlimab and tuvonralimab with chemotherapy for locally advanced cervical cancer

  This phase 2 trial tests whether giving iparomlimab and tuvonralimab with chemotherapy before surgery helps people with locally advanced cervical cancer shrink their tumors and improve outcomes.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian · NCT07055399

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.